Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company's primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway. Its product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. AQX-1125 is a SHIP1 activator that has demonstrated preliminary safety, anti-inflammatory potential and drug properties in multiple preclinical studies.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:AQXP
- CUSIP: N/A
- Web: www.aqxpharma.com
Capitalization:- Market Cap: $343.61 million
- Outstanding Shares: 23,423,000
Average Prices:- 50 Day Moving Avg: $13.98
- 200 Day Moving Avg: $15.96
- 52 Week Range: $6.01 - $19.97
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.27
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $5.85 per share
- Price / Book: 2.57
Profitability:- Return on Equity: -29.19%
- Return on Assets: -27.46%
Debt:- Current Ratio: 21.04%
- Quick Ratio: 21.04%
Misc:- Average Volume: 85,706 shs.
- Beta: -17.04
- Short Ratio: 16.11
Frequently Asked Questions for Aquinox Pharmaceuticals (NASDAQ:AQXP)
What is Aquinox Pharmaceuticals' stock symbol?
Aquinox Pharmaceuticals trades on the NASDAQ under the ticker symbol "AQXP."
How were Aquinox Pharmaceuticals' earnings last quarter?
Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) posted its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.51) by $0.15. During the same quarter last year, the company earned ($0.39) earnings per share. View Aquinox Pharmaceuticals' Earnings History.
When will Aquinox Pharmaceuticals make its next earnings announcement?
Where is Aquinox Pharmaceuticals' stock going? Where will Aquinox Pharmaceuticals' stock price be in 2017?
5 equities research analysts have issued twelve-month price objectives for Aquinox Pharmaceuticals' shares. Their forecasts range from $9.00 to $28.00. On average, they anticipate Aquinox Pharmaceuticals' stock price to reach $20.75 in the next twelve months. View Analyst Ratings for Aquinox Pharmaceuticals.
Who are some of Aquinox Pharmaceuticals' key competitors?
Some companies that are related to Aquinox Pharmaceuticals include AMAG Pharmaceuticals (AMAG), SciClone Pharmaceuticals (SCLN), Teligent (TLGT), Aceto Corporation (ACET), Collegium Pharmaceutical (COLL), Tetraphase Pharmaceuticals (TTPH), Corium International (CORI), Neos Therapeutics (NEOS), BioDelivery Sciences International (BDSI), Allergy Therapeutics plc (AGY), Adamis Pharmaceuticals Corporation (ADMP), Aralez Pharmaceuticals (ARLZ), Concordia International Corp. (CXRX), Diurnal Group PLC (DNL), Innocoll Holdings (INNL), Neuralstem (CUR), Intellipharmaceutics International (IPCI) and Amryt Pharma PLC (AMYT).
Who are Aquinox Pharmaceuticals' key executives?
Aquinox Pharmaceuticals' management team includes the folowing people:
- David J. Main, Co-Founder, President and Chief Executive Officer and Chairman of the Board
- Kamran Alam, Chief Financial Officer, Vice President - Finance
- Lloyd Mackenzie, Vice President - Technical Operations and Planning
- David Chilton Mitchell, Vice President - Global Regulatory Affairs & Quality Assurance
- Barbara Troupin M.D., Chief Medical Officer, Vice President - Clinical Development
- Robert E. Pelzer, Lead Independent Director
- Gary J. Bridger Ph.D., Director
- Daniel J. Levitt M.D., Ph.D., Director
- Richard S. Levy M.D., Director
- Kelvin M. Neu M.D., Director
Who owns Aquinox Pharmaceuticals stock?
Aquinox Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include RA Capital Management LLC (9.32%), Goldman Sachs Group Inc. (4.13%), Boxer Capital LLC (3.75%), Vanguard Group Inc. (0.00%), Eventide Asset Management LLC (0.75%) and Royce & Associates LP (0.00%). Company insiders that own Aquinox Pharmaceuticals stock include Bros Advisors Lp Baker, David Chilton Mitchell, David Main, Kamran Alam and Lloyd Mackenzie. View Institutional Ownership Trends for Aquinox Pharmaceuticals.
Who sold Aquinox Pharmaceuticals stock? Who is selling Aquinox Pharmaceuticals stock?
Aquinox Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Emory University, Royce & Associates LP, RA Capital Management LLC, ProShare Advisors LLC, Goldman Sachs Group Inc., TD Asset Management Inc. and Bank of New York Mellon Corp. View Insider Buying and Selling for Aquinox Pharmaceuticals.
Who bought Aquinox Pharmaceuticals stock? Who is buying Aquinox Pharmaceuticals stock?
Aquinox Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Geode Capital Management LLC and Investment Centers of America Inc.. Company insiders that have bought Aquinox Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker and David Chilton Mitchell. View Insider Buying and Selling for Aquinox Pharmaceuticals.
How do I buy Aquinox Pharmaceuticals stock?
Shares of Aquinox Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aquinox Pharmaceuticals' stock price today?
One share of Aquinox Pharmaceuticals stock can currently be purchased for approximately $15.05.
MarketBeat Community Rating for Aquinox Pharmaceuticals (NASDAQ AQXP)MarketBeat's community ratings are surveys of what our community members think about Aquinox Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Aquinox Pharmaceuticals (NASDAQ:AQXP) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.80) |
| Consensus Price Target: | $20.75 (37.87% upside) |
Analysts' Ratings History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/9/2017 | Cantor Fitzgerald | Set Price Target | Buy | $28.00 | Low |  |
| 11/11/2016 | Leerink Swann | Reiterated Rating | Buy | $24.00 | N/A | |
| 11/10/2016 | Needham & Company LLC | Reiterated Rating | Buy | | N/A | |
| 8/17/2016 | Canaccord Genuity | Reiterated Rating | Buy | $22.00 | N/A | |
| 8/5/2016 | Jefferies Group LLC | Boost Price Target | Hold | $7.00 -> $9.00 | N/A | |
| 11/3/2015 | Cowen and Company | Reiterated Rating | Buy | $23.00 | N/A | |
| 10/6/2015 | Guggenheim | Initiated Coverage | Buy | $22.00 | N/A | |
(Data available from 6/24/2015 forward)
Earnings History for Aquinox Pharmaceuticals (NASDAQ:AQXP)Earnings History by Quarter for Aquinox Pharmaceuticals (NASDAQ AQXP)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/2/2017 | | | | | | | | |
| 5/9/2017 | 3/31/2017 | ($0.51) | ($0.36) | | | View | N/A | |
| 3/9/2017 | 12/31/2016 | ($0.51) | ($0.48) | | | View | Listen | |
| 11/9/2016 | Q316 | ($0.58) | ($0.46) | | | View | N/A | |
| 8/4/2016 | Q2 | ($0.41) | ($0.63) | | | View | N/A | |
| 5/10/2016 | Q1 | ($0.35) | ($0.39) | | | View | N/A | |
| 11/10/2015 | Q315 | ($0.45) | ($0.43) | | | View | N/A | |
| 8/6/2015 | Q215 | ($0.56) | ($0.44) | | | View | N/A | |
| 5/12/2015 | Q115 | ($0.83) | ($0.60) | | | View | N/A | |
| 4/15/2015 | | ($0.57) | ($0.78) | | | View | N/A | |
| 3/16/2015 | Q4 2014 | ($0.76) | ($0.78) | | | View | N/A | |
| 11/4/2014 | Q3 2014 | ($0.29) | ($0.59) | | | View | N/A | |
| 8/11/2014 | Q2 2014 | ($0.27) | ($0.51) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Aquinox Pharmaceuticals (NASDAQ:AQXP)2017 EPS Consensus Estimate: ($2.43)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.57) | ($0.57) | ($0.57) |
| Q2 2017 | 1 | ($0.59) | ($0.59) | ($0.59) |
| Q3 2017 | 1 | ($0.62) | ($0.62) | ($0.62) |
| Q4 2017 | 1 | ($0.65) | ($0.65) | ($0.65) |
(Data provided by Zacks Investment Research)
Dividend History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Aquinox Pharmaceuticals (NASDAQ:AQXP)Insider Ownership Percentage: 2.70%
Institutional Ownership Percentage: 98.36%
Insider Trades by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/5/2017 | David Main | Insider | Sell | 15,625 | $13.26 | $207,187.50 | |
| 1/9/2017 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 398,062 | $17.18 | $6,838,705.16 | |
| 9/20/2016 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 2,783,605 | $12.25 | $34,099,161.25 | |
| 3/16/2016 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 471,667 | $7.99 | $3,768,619.33 | |
| 3/15/2016 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 109,912 | $7.98 | $877,097.76 | |
| 1/26/2016 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 140,786 | $10.80 | $1,520,488.80 | |
| 1/20/2016 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 112,034 | $9.48 | $1,062,082.32 | |
| 1/19/2016 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 78,045 | $9.11 | $710,989.95 | |
| 1/15/2016 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 202,623 | $8.28 | $1,677,718.44 | |
| 9/10/2015 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 2,480,032 | $15.50 | $38,440,496.00 | |
| 8/24/2015 | David Chilton Mitchell | VP | Buy | 3,575 | $17.81 | $63,670.75 | |
| 8/12/2015 | Kamran Alam | CFO | Sell | 29,079 | $18.67 | $542,904.93 | |
| 8/12/2015 | Lloyd Mackenzie | VP | Sell | 35,887 | $18.67 | $670,010.29 | |
| 12/17/2014 | & Johnson Johnson | Major Shareholder | Sell | 8,100 | $7.62 | $61,722.00 | |
| 12/12/2014 | & Johnson Johnson | Major Shareholder | Sell | 5,000 | $7.51 | $37,550.00 | |
| 12/10/2014 | & Johnson Johnson | Major Shareholder | Sell | 8,300 | $7.72 | $64,076.00 | |
| 12/9/2014 | & Johnson Johnson | Major Shareholder | Sell | 5,000 | $7.73 | $38,650.00 | |
| 12/8/2014 | & Johnson Johnson | Major Shareholder | Sell | 2,000 | $7.69 | $15,380.00 | |
| 12/5/2014 | & Johnson Johnson | Major Shareholder | Sell | 15,900 | $7.76 | $123,384.00 | |
| 12/1/2014 | & Johnson Johnson | Major Shareholder | Sell | 1,200 | $7.54 | $9,048.00 | |
| 11/26/2014 | & Johnson Johnson | Major Shareholder | Sell | 2,000 | $7.75 | $15,500.00 | |
| 11/24/2014 | & Johnson Johnson | Major Shareholder | Sell | 9,500 | $8.14 | $77,330.00 | |
| 3/12/2014 | Pfizer Inc | Major Shareholder | Buy | 272,727 | $11.00 | $2,999,997.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Latest Headlines for Aquinox Pharmaceuticals (NASDAQ:AQXP)
| Source: |
|
| Date | Headline |
|---|
 | Brokerages Expect Aquinox Pharmaceuticals, Inc. (AQXP) Will Announce Earnings of -$0.59 Per Share
www.americanbankingnews.com - June 19 at 10:28 PM |
| Aquinox Pharmaceuticals, Inc. (AQXP) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - June 13 at 1:00 AM |
| Aquinox Pharmaceuticals Inc (AQXP) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - June 6 at 2:38 PM |
| Insider Selling: Aquinox Pharmaceuticals Inc (AQXP) Insider Sells 15,625 Shares of Stock
www.americanbankingnews.com - June 5 at 8:07 PM |
 | Supernus Pharmaceuticals (SUPN) Jumps: Stock Rises 6.2%
finance.yahoo.com - June 1 at 3:50 PM |
| Aquinox to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 1 at 3:50 PM |
| Aquinox Pharmaceuticals Inc Forecasted to Earn FY2017 Earnings of ($2.24) Per Share (AQXP)
www.americanbankingnews.com - May 15 at 8:54 AM |
| Short Interest in Aquinox Pharmaceuticals Inc (AQXP) Declines By 19.6%
www.americanbankingnews.com - May 14 at 9:14 AM |
| Aquinox Pharmaceuticals Inc (AQXP) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 12 at 2:38 PM |
| Aquinox Pharmaceuticals Inc (AQXP) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - May 11 at 10:52 PM |
 | BRIEF-Aquinox Pharmaceuticals Qtrly loss per share $0.36
www.reuters.com - May 11 at 3:59 PM |
| Research Analysts Issue Forecasts for Aquinox Pharmaceuticals Inc's FY2017 Earnings (AQXP)
www.americanbankingnews.com - May 11 at 11:42 AM |
| Aquinox Pharmaceuticals Inc (AQXP) Given a $28.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - May 9 at 11:36 PM |
| Zacks Investment Research Downgrades Aquinox Pharmaceuticals Inc (AQXP) to Hold
www.americanbankingnews.com - May 9 at 4:38 PM |
| Aquinox Pharmaceuticals Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 3:35 PM |
| Aquinox reports 1Q loss
finance.yahoo.com - May 9 at 3:35 PM |
| Aquinox Pharmaceuticals Inc (AQXP) Announces Earnings Results, Beats Estimates By $0.15 EPS
www.americanbankingnews.com - May 9 at 11:24 AM |
| Aquinox Pharmaceuticals Inc (AQXP) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - May 5 at 11:12 PM |
| Aquinox Pharmaceuticals Inc (AQXP) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - May 5 at 10:46 PM |
| Aquinox Pharmaceuticals Inc (AQXP) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - May 5 at 10:23 PM |
| Aquinox Pharmaceuticals (AQXP) Earns News Sentiment Rating of 0.10
www.americanbankingnews.com - May 2 at 7:26 PM |
| Zacks: Brokerages Expect Aquinox Pharmaceuticals Inc (AQXP) to Announce -$0.57 Earnings Per Share
www.americanbankingnews.com - May 1 at 7:46 PM |
| Aquinox Pharmaceuticals (AQXP) Given Daily Coverage Optimism Rating of 0.04
www.americanbankingnews.com - April 27 at 2:42 PM |
| Aquinox to Present at 2017 Bloom Burton & Co. Healthcare Investor Conference
finance.yahoo.com - April 26 at 8:58 AM |
| Aquinox Pharmaceuticals (AQXP) Receives Daily News Sentiment Score of 0.02
www.americanbankingnews.com - April 23 at 8:22 AM |
| Somewhat Favorable Media Coverage Very Unlikely to Affect Aquinox Pharmaceuticals (AQXP) Share Price
www.americanbankingnews.com - April 20 at 2:40 PM |
| Aquinox Pharmaceuticals Inc (AQXP) Sees Large Decline in Short Interest
www.americanbankingnews.com - April 19 at 7:08 AM |
| Aquinox Pharmaceuticals Inc (AQXP) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 17 at 5:08 PM |
| Aquinox Pharmaceuticals (AQXP) Receiving Somewhat Critical News Coverage, Report Finds
www.americanbankingnews.com - April 17 at 12:04 PM |
| Somewhat Favorable Press Coverage Somewhat Likely to Impact Aquinox Pharmaceuticals (AQXP) Stock Price
www.americanbankingnews.com - April 14 at 4:40 PM |
| Aquinox Pharmaceuticals Inc (AQXP) Expected to Post Quarterly Sales of $0.00
www.americanbankingnews.com - April 12 at 11:56 AM |
| Aquinox to Present at the 16th Annual Needham Healthcare Conference
finance.yahoo.com - March 29 at 8:48 PM |
 | Aquinox Pharma (AQXP) Names Kelvin Neu and Richard Levy to Board of Directors
www.streetinsider.com - March 28 at 10:31 AM |
| AQUINOX PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and
biz.yahoo.com - March 28 at 10:31 AM |
| Aquinox Announces Appointment of Dr. Kelvin Neu and Dr. Richard Levy to Board of Directors
finance.yahoo.com - March 28 at 10:31 AM |
| 6:23 pm Aquinox Pharma announced that representatives from Aquinox's largest shareholder, Baker Brothers Investments, have been appointed to the Aquinox's board of directors
finance.yahoo.com - March 28 at 10:31 AM |
| Aquinox Pharmaceuticals Inc (AQXP) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - March 23 at 6:25 PM |
| Aquinox Pharmaceuticals Inc (AQXP) to Post FY2017 Earnings of ($2.30) Per Share, Cantor Fitzgerald Forecasts
www.americanbankingnews.com - March 23 at 9:32 AM |
 | Aquinox Pharmaceuticals (AQXP) Presents At Oppenheimer 27th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 22 at 9:08 PM |
| Aquinox Pharmaceuticals Inc (AQXP) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 22 at 12:46 PM |
| Aquinox Pharmaceuticals Inc (AQXP) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 20 at 9:55 AM |
| AQUINOX PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 16 at 5:06 PM |
| AQUINOX PHARMACEUTICALS, INC Financials
finance.yahoo.com - March 15 at 3:47 PM |
| Aquinox to Present at the Oppenheimer & Co. 27th Annual Healthcare Conference
finance.yahoo.com - March 14 at 8:35 PM |
| Aquinox Pharmaceuticals Inc Forecasted to Post FY2021 Earnings of $0.30 Per Share (AQXP)
www.americanbankingnews.com - March 13 at 2:48 PM |
| Aquinox Pharmaceuticals Inc (AQXP) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - March 11 at 7:21 PM |
| Aquinox Pharmaceuticals' (AQXP) CEO David Main on Q4 2016 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 10 at 4:21 PM |
| AQUINOX PHARMACEUTICALS, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
biz.yahoo.com - March 9 at 9:13 PM |
| Q4 2016 Aquinox Pharmaceuticals Inc Earnings Release - After Market Close
biz.yahoo.com - March 9 at 4:12 PM |
| Aquinox Pharmaceuticals Announces Year End 2016 Financial Results
finance.yahoo.com - March 9 at 4:12 PM |
Aquinox Pharmaceuticals (AQXP) Chart for Saturday, June, 24, 2017
